Edwards Lifesciences, a leader in structural heart disease solutions, has shown significant growth, particularly in its heart-related therapies segment, which reported a 42% year-over-year increase in Q1 2026. Following a stronger-than-expected earnings report, the company raised its full-year sales growth guidance to 9%–11%, projecting revenues between $6.5 billion and $6.9 billion.
Adjusted EPS guidance was also increased to $2.95–$3.05, with an expected operating margin expansion. The stock has recently broken out of a consolidation phase, with a price range between $75 and $87, and has shown resilience by holding above the $81 level after a retest.
This breakout, combined with solid fundamentals and increasing buyer momentum, positions Edwards Lifesciences favorably for continued growth. Investors should monitor the $81 support level closely, as a drop below this could indicate a shift in market sentiment